Mary Beattie

Pathology of Breast and Ovarian Cancers among <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Results from the Consortium of Investigators of Modifiers of <i>BRCA1</i> / <i>2</i> (CIMBA)

Nasim Mavaddat, Daniel Barrowdale, Irene L. Andrulis et al. · Cancer Epidemiology Biomarkers & Prevention · 2012 · 668 citations · Full text

Medicine, Genetics, Oncology +15

Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study

Funda Meric‐Bernstam, Herbert I. Hurwitz, Kanwal Raghav et al. · The Lancet Oncology · 2019 · 564 citations

Medicine, Oncology, Pharmacology +14

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study

John D. Hainsworth, Funda Meric‐Bernstam, Charles Swanton et al. · Journal of Clinical Oncology · 2018 · 505 citations · Full text

Medicine, Oncology, Pharmacology +17

Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk

Fergus J. Couch, Xianshu Wang, Lesley McGuffog et al. · PLoS Genetics · 2013 · 391 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

Risk-Reducing Salpingo-Oophorectomy in <i>BRCA</i> Mutation Carriers: Role of Serial Sectioning in the Detection of Occult Malignancy

C. Bethan Powell, Eric Kenley, Lee-may Chen et al. · Journal of Clinical Oncology · 2004 · 375 citations · Full text

Medicine, Gynecology, Surgery +16